Target intelligence / Profile preview

Cyclic AMP-specific phosphodiesterase 4 (PDE4)

Target
PDE4
Molecular classification
Enzyme, Phosphodiesterase family member
01

Overview

Cyclic AMP-specific phosphodiesterase 4 (PDE4) is an enzyme that hydrolyzes cyclic adenosine monophosphate (cAMP) into inactive adenosine monophosphate (AMP), thereby regulating cellular concentrations of this critical second messenger. The enzyme plays a central role in controlling both the magnitude and duration of cAMP-mediated signaling within cells. There are four genes encoding multiple isoforms within the PDE4 family, each with distinct regulatory sequences allowing tissue-, cell-, or even subcellular-compartment–specific expression patterns. These isoforms underpin compartmentalized cAMP signaling crucial for diverse physiological processes including immune response modulation, neuronal plasticity, inflammation control, cardiovascular function regulation, and more. Pharmacological inhibition of PDE4 leads to increased intracellular cAMP levels which exerts anti-inflammatory effects by suppressing pro-inflammatory cytokines while enhancing anti-inflammatory mediators. This has made PDE4 a validated therapeutic target in diseases such as chronic obstructive pulmonary disease (COPD), psoriasis/psoriatic arthritis, atopic dermatitis, certain psychiatric conditions like depression or schizophrenia—and it is under investigation for substance dependence therapies. Despite their promise as drug targets across multiple indications—including inflammatory diseases and CNS disorders—the clinical development of broad-spectrum PDE4 inhibitors has been limited by dose-limiting gastrointestinal side effects such as nausea/emesis. These adverse events are believed to be related primarily to inhibition of specific subtypes like PDE4D, especially outside intended target tissues.

Other names
Phosphodiesterase 4PDE4cAMP-specific phosphodiesterase 4Cyclic nucleotide phosphodiesterases, type 4
02

Mechanism of action

Inhibition of PDE4 increases intracellular cAMP levels by blocking its degradation, leading to anti-inflammatory and neuroprotective effects as well as modulation of immune cell function and neurotransmission.

03

Biological functions

Hydrolysis of cyclic AMP (cAMP) to inactive adenosine monophosphate (AMP)Regulation of intracellular cAMP signaling and compartmentalization
04

Disease associations

Inflammation (e.g., asthma, COPD, psoriasis)Neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease)Psychiatric disorders (e.g., depression, schizophrenia)Substance dependence/addiction
05

Safety considerations

Nausea and emesis/gastrointestinal side effects are common with non-selective PDE4 inhibition due to off-target activity in non-diseased tissues—especially via inhibition of the PDE4D subtype in the area postrema.Narrow therapeutic window limits dosing for many indications.Diarrhea and abdominal pain also reported frequently with systemic inhibitors.
06

Interacting drugs

Roflumilast

4 more in the full profile.

Beyond the preview

Go deeper on Cyclic AMP-specific phosphodiesterase 4 (PDE4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclic AMP-specific phosphodiesterase 4 (PDE4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call